[go: up one dir, main page]

KR920703638A - 세포증식을 저해하는 TGF-β 단백질 조성물 - Google Patents

세포증식을 저해하는 TGF-β 단백질 조성물

Info

Publication number
KR920703638A
KR920703638A KR1019920700547A KR920700547A KR920703638A KR 920703638 A KR920703638 A KR 920703638A KR 1019920700547 A KR1019920700547 A KR 1019920700547A KR 920700547 A KR920700547 A KR 920700547A KR 920703638 A KR920703638 A KR 920703638A
Authority
KR
South Korea
Prior art keywords
tgf
collagen
matrix
concentration
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019920700547A
Other languages
English (en)
Inventor
앰. 브라운 데니스
루크 에드워드
알. 트와드지크 다니엘
애프. 퓨르치오. 안토니
Original Assignee
원본미기재
온코겐 리미티드 파트너쉽
메트릭스 파라마티컬 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 온코겐 리미티드 파트너쉽, 메트릭스 파라마티컬 인코포레이티드 filed Critical 원본미기재
Publication of KR920703638A publication Critical patent/KR920703638A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

세포증식을 저해하는 TGF-β 단백질 조성물
[도면의 간단한 설명]
제1도는 시간에 대한 CM-TGF-β (CM 농도: 40, 30, 20 또는 10mg/㎖)에서 방사선 라벨된 TCF-β 해리를 나타낸 것이다.
제2도는 시간에 대한 세포성장 저해도를 측정하여 CM-TGF-β (40mg/㎖ CM 농도)에서 TGF-β-의 유출 퍼센트 비율을 나타낸 것이다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. TGF-β의 적어도 8개의 아미노산과 단백질을 포함하는 메트릭스로 구성된 것을 특징으로 하는 조성물.
  2. 제1항에 있어서, TGF-β가 TGF-β1 또는 TGF-β2인 것을 특징으로 하는 조성물.
  3. 제1항에 있어서, 단백질 포함 매질은 콜라겐과 피브리노겐중 적어도 하나로 구성된 것을 포함하는 성분물.
  4. 제3항에 있어서, 단백질 포함 매질에서 콜라겐 농도가 10mg/㎖ 내지 40mg/㎖인 것을 특징으로 하는 성분물.
  5. 제4항에 있어서, 콜라겐 농도가 30mg/㎖인 것을 특징으로 하는 성분물.
  6. 콜라겐의 농도가 10mg/㎖내지 40mg/㎖ 포함된 매질과 TGF-β 농도가 1mg/㎖내지 10mg/㎖ 콜라겐인 것으로 구성된 것을 특징으로 하는 성분물.
  7. 제6항에 있어서, TGF-β가 원숭이 TGF-β1인 것을 특징으로 하는 성분물.
  8. 적정량의 TGF-β1과 TGF-β2 중 적어도 하나와 콜라겐 메트릭스로 구성되고 메트릭스에서 TGF-β1과 TGF-β2가 배출될때 표식세포의 증식을 저해하는 것을 특징으로 하는 성분물.
  9. TGF-β에 민감한 세포의 증식억제 저해 방법에 있어서, 단백질 포함 매트릭스와 적어도 하나의 TGF-β 적정량으로 구성된 증식 억제 성분물로 세포에 주입하고 매트릭스에서 증식억제 성분이 배출되어 세포의 증식억제 효과를 발휘하는 것을 특징으로 하는 방법.
  10. 제9항에 있어서, 단백질 포함매질에는 콜라겐과 피브리노겐중 적어도 하나가 포함되는 것을 특징으로 하는 방법.
  11. 제10항에 있어서, TGF-β가 원숭이 TGF-β1인 것을 특징으로 하는 방법.
  12. 제11항에 있어서, 콜라겐 메트릭스에는 TGF-β1이 1mg/㎖내지 10mg/㎖ 콜라겐이 포함된 것을 특징으로 하는 방법.
  13. 제12항에 있어서, 콜라겐 농도가 10내지 40mg/㎖인 것을 특징으로 하는 방법.
  14. 제10항에 있어서, 증식억제 성분물에는 단백질 포함 매질에서 TGF-β 확산을 지체시키기 위해 혈관 수축물질이 추가로 포함되는 것을 특징으로 하는 방법.
  15. 제14항에 있어서, 혈관수축물질이 에피네프린인 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700547A 1989-09-11 1990-09-10 세포증식을 저해하는 TGF-β 단백질 조성물 Withdrawn KR920703638A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40553489A 1989-09-11 1989-09-11
US405.534 1989-09-11
PCT/US1990/005091 WO1991003491A1 (en) 1989-09-11 1990-09-10 TGF-β PROTEIN COMPOSITIONS FOR INHIBITION OF CELL PROLIFERATION

Publications (1)

Publication Number Publication Date
KR920703638A true KR920703638A (ko) 1992-12-18

Family

ID=23604101

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700547A Withdrawn KR920703638A (ko) 1989-09-11 1990-09-10 세포증식을 저해하는 TGF-β 단백질 조성물

Country Status (14)

Country Link
US (1) US5597578A (ko)
EP (1) EP0485530A4 (ko)
JP (1) JPH05500225A (ko)
KR (1) KR920703638A (ko)
AU (1) AU646820B2 (ko)
CA (1) CA2066228A1 (ko)
DD (1) DD299310A5 (ko)
FI (1) FI921036A0 (ko)
GR (1) GR900100681A (ko)
IE (1) IE903275A1 (ko)
IL (1) IL95500A (ko)
NZ (1) NZ235167A (ko)
PT (1) PT95285B (ko)
WO (1) WO1991003491A1 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
AU8702491A (en) * 1990-11-08 1992-05-14 Matrix Pharmaceutical, Inc. Fibrin/collagen membrane material for biomedical use
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5824647A (en) * 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
ATE377418T1 (de) * 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US6309670B1 (en) * 1997-01-15 2001-10-30 Orquest, Inc. Collagen-polysaccharide matrix for treatment of bone tumors
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
DE19841698A1 (de) * 1998-09-11 2000-03-16 Curative Technologies Gmbh Wachstumsfaktor-enthaltende Zusammensetzung zur Heilung von Gewebeschäden
US6103695A (en) * 1998-10-14 2000-08-15 Vanderbilt University Method of producing pleurodesis
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US7671014B2 (en) 2006-08-14 2010-03-02 Warsaw Orthopedic, Inc. Flowable carrier matrix and methods for delivering to a patient
US20080154372A1 (en) * 2006-12-21 2008-06-26 Peckham Steven M Osteochondral implant using a growth factor concentration gradient for repair of bone and cartilage tissue
EP1961414A1 (en) * 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition comprising a recombinant gelatin
EP1961411A1 (en) * 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition
EP2112998B1 (en) * 2007-02-21 2012-04-18 FUJIFILM Manufacturing Europe B.V. Rgd containing recombinant gelatin
US9616153B2 (en) 2008-04-17 2017-04-11 Warsaw Orthopedic, Inc. Rigid bone graft substitute
ES2762214T3 (es) * 2011-10-21 2020-05-22 Betaglue Tech S P A Compuesto antitumoral y proceso de producción relativo
NL2016403B1 (en) 2016-03-09 2017-09-26 Douwe Egberts Bv Assembly and method for frothing fluid.
DE102016212892C5 (de) * 2016-07-14 2020-01-30 F. Holzer Gmbh Pumpkopf sowie Dosiervorrichtung
US11141526B2 (en) 2019-11-01 2021-10-12 BetaGlue Technologies S.p.A Compositions, devices and kits for selective internal radiation therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837285A (en) * 1984-03-27 1989-06-06 Medimatrix Collagen matrix beads for soft tissue repair
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4620327A (en) * 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
ATE128715T1 (de) * 1984-07-16 1995-10-15 Celtrix Pharma Polypeptide induzierende faktoren in knochen und knorpel.
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
US4816442A (en) * 1986-11-07 1989-03-28 Collagen Corporation Method of inhibiting tumor growth sensitive to CIF-βtreatment
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal

Also Published As

Publication number Publication date
AU646820B2 (en) 1994-03-10
PT95285B (pt) 1998-04-30
PT95285A (pt) 1991-05-22
IE903275A1 (en) 1991-04-10
WO1991003491A1 (en) 1991-03-21
IL95500A0 (en) 1991-06-30
EP0485530A1 (en) 1992-05-20
GR900100681A (el) 1992-01-20
FI921036A7 (fi) 1992-03-10
IL95500A (en) 1997-03-18
DD299310A5 (de) 1992-04-09
FI921036A0 (fi) 1992-03-10
JPH05500225A (ja) 1993-01-21
NZ235167A (en) 1993-03-26
US5597578A (en) 1997-01-28
AU6507490A (en) 1991-04-08
CA2066228A1 (en) 1991-03-12
EP0485530A4 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
KR920703638A (ko) 세포증식을 저해하는 TGF-β 단백질 조성물
ES2072452T3 (es) Medios cosmeticos desodorizantes.
ATE189611T1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
DE69519566D1 (de) Mittel zur kuenstliche braunung mit verbesserte farbe entwicklung
DE69032963D1 (de) (Modifiziertes) hydriertes Dien-Blockcopolymer und dieses enthaltende Zusammensetzung
DE69637356D1 (de) Beschichtungs oder versiegelungszusammensetzung
NO973291D0 (no) Næringspreparat oppnådd etter stöping av mais, samt fremstilling derav
NO891411L (no) Stempel/sylinder-motor med roterende sylinderblokk.
ES2107124T3 (es) Procedimiento para inhibir la actividad de endotoxinas.
NO901759L (no) Dipeptid-derivater med enzym-hemmende virkning.
ATE214803T1 (de) Stabilisierte standards und kalibratoren
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
WO2003007733A8 (en) Protein-containing foodstuff comprising a cross-linking enzyme and a hydrocolloid
TR199900561T2 (xx) G-protein i�levinin engellenmesi i�in ve �o�almaya y�nelik hastal�klar�n iyile�tirilmesi i�in yararl� trisiklik bile�ikler.
ES2046422T3 (es) Composicion antimicrobiana y metodo de uso.
ATE109006T1 (de) Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.
ATE222758T1 (de) S-alkylisothiouronium-derivate enthaltende pharmazeutische zusammensetzungen
NO894944D0 (no) Dipeptid-derivater med enzym-hemmende virkning.
DE68906167D1 (de) Zusammensetzung zur erkennung von paradontalen krankheiten.
EP0588036A3 (en) Composition for the isolation of apamine receptor, apamine binding protein and its uses.
AU8855798A (en) Novel composition for treating, preventing and/or delaying ischemic cell death
ATE146526T1 (de) Neues thrombininhibitorisches protein aus zecken
KR980002252A (ko) 미리스티신을 유효성분으로 포함하는 시토크롬 p450 효소의 합성증강제
FR2778851B1 (fr) Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
SE9502927D0 (sv) Solution containing IGF-I

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920311

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid